Company profile for Acepodia

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The mission of Acepodia, Inc. is to develop safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with our current primary focus in oncology. Our collaboration ranges from academies, hospitals to industries. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepod...
The mission of Acepodia, Inc. is to develop safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with our current primary focus in oncology. Our collaboration ranges from academies, hospitals to industries. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Taiwan
Address
Address
Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd., Sijhih Dist., New Taipei City 2217...
Telephone
Telephone
+886-2-26976100
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/acepodia-presents-preclinical-data-on-antibody-dual-drugs-conjugation-ad2c-technology-at-aacr-annual-meeting-2025-302433216.html

PR NEWSWIRE
21 Apr 2025

https://www.businesswire.com/news/home/20250107874851/en

BUSINESSWIRE
07 Jan 2025

https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831-in-igg4-related-disease-302306506.html

PR NEWSWIRE
15 Nov 2024

https://www.fiercebiotech.com/biotech/acepodia-and-pfizer-ignite-click-together-advance-chemistry-based-cell-therapies

FIERCE BIOTECH
03 Sep 2024

https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html

PR NEWSWIRE
04 Feb 2024
Nobel laureate Carolyn Bertozzi joins cancer-focused Acepodia
Nobel laureate Carolyn Bertozzi joins cancer-focused Acepodia

18 Sep 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/nobel-laureate-bertozzi-joins-acepodia-biotech-aims-transform-cancer-cell-therapy

Gabrielle Masson FIERCE BIOTECH
18 Sep 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty